Biogen Stock News

Biogen Idec was notified by a European Medicines Agency (EMA) panel of experts that its Alzheimers treatment Aduhelm is "unlikely" to win their approval, the United States biotechnolo

Following an oral explanation held at the November meeting of the EMA's human medicines committee, Biogen Inc (NASDAQ: BIIB) received "a negative trend vote" on its marketing application for its con

Biogen Inc. shares BIIB, -3.78% slid 4% in premarket trade Wednesday, after the company said it had received a "negative trend vote" from an advisory committee to the European Medicines Agency for its

Biogen is benefiting from a first-mover advantage, but the race is far from over.

Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,

The post I like Eli Lilly over Biogen and Cassava Sciences appeared on BitcoinEthereumNews.com . Cassava Sciences: This is not the one. I dont think they have it. I dont think Biogen has it, even though Medicare is going to pay for it. I think

Related Stocks: LLY , ABBV , GRPH , VINC , KYMR , RUN , PFE , PANW , BMRN , IMTX , OMGA , NKE , MRK , LPSN , VRNS , RACA , BIIB , STTK ,

PALM BEACH, Fla. , Nov. 16, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. Also, the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, to be postponed unless the risks outweighed the benefits and to secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the cancer therapy market. However, the situation is expected to gradually improve. According to a report from Mordor Intelligence the global cancer therapy market was valued at approximately USD 158 billion in 2020, and it is expected to witness a revenue of USD 268 billion in 2026, with a CAGR of 9.15% over the forecast period.

The European Commission has approved Biogen Inc's (NASDAQ: BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS). Vumerity is next-generation fumarate

Comerica Bank reduced its holdings in Biogen Inc. (NASDAQ:BIIB) by 7.7% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 23,678 shares of the biotechnology companys stock after selling 1,971 shares during the period. Comerica Banks holdings in Biogen were worth $8,018,000 at the end of the most recent reporting period. Several other large []

Global Berryliosis Treatment Market Synopsis: The finest Berryliosis Treatment Market analysis document enumerates information about the key companies based on their Market position in the present scenario along with data related to the Market sales gathered by the manufacturers along with

Late Monday, Biogen made the surprise announcement that Dr. Alfred Sandrock, the man most closely associated with its controversial Alzheimer's disease therapy, will retire at the end of the year. Bio

CAMBRIDGE, Mass., Nov. 15, 2021. (Nasdaq: BIIB) announced today that Alfred "Al" W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company effective December 31, 2

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) announced today that Alfred Al W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company effective December 31, 2021. A 23-year veteran of Biogen, Dr. Sandrock, 64, led the development of many of the Companys most important and transformational therapies in neurological diseases, including Tysabri ® (natalizumab), Tecfidera ® (dimethyl fumarate), Spinraza ® (nusinersen), Plegridy ® (peginterferon beta-1a) and Aduhelm (aducanumab-avwa). Dr. Sandrock served on Biogens Executive Committee since 2015, as Head of Research & Development since October 2019, and as Chief Medical Officer from 2012 to 2020.

Al Sandrock, Biogens top scientist and the face of its years-long campaign to develop a treatment for Alzheimers disease, is leaving the company after more than two decades, STAT has